ACM
APLS

ADAR1 Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

ADAR1 Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$3.84K – 285
2024
Q2 		$3.84K Buy
+100
New +$4.53K ﹤0.01% 249

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ADAR1 Capital Management's APLS Position: Q1 2026 in Review

ADAR1 Capital Management increased its Apellis Pharmaceuticals (APLS) stake by 263% in Q1 2026, buying an estimated $1.13M and bringing the position to 72,500 shares worth $2.92M. The position accounts for 0.17% of the portfolio, ranked #109.

ADAR1 Capital Management first reported a position in APLS in Q1 2024 and has held it in 9 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • ADAR1 Capital Management held 72,500 shares of Apellis Pharmaceuticals worth $2.92M as of Q1 2026.
  • ADAR1 Capital Management bought 52,500 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.13M.
  • Apellis Pharmaceuticals made up 0.17% of ADAR1 Capital Management's portfolio in Q1 2026, its #109 holding.
  • ADAR1 Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.